Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00218036 |
Recruitment Status
: Unknown
Verified December 2009 by National Institute on Drug Abuse (NIDA).
Recruitment status was: Recruiting
First Posted
: September 22, 2005
Last Update Posted
: December 15, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cocaine Abuse Opiate Dependence | Drug: Modafinil 200mg Drug: Modafinil 400mg Drug: Citalopram 20mg Drug: Citalopram 40mg Drug: Placebo | Phase 2 |
This is a 24-week, randomized, double-blind, placebo-controlled study examining two doses of modafinil (200 and 400 mg) and citalopram (20 and 40 mg) in the treatment of methadone maintained cocaine dependent individuals.
Participants will first be given methadone to determine its tolerated and effective doses. Most participants will be able to reach a stable dose of methadone within 7 to 10 days of methadone initiation. When 80% of the projected dose of methadone has been achieved, participants will begin the medication regimen of modafinil or citalopram. Modafinil will be given over a 7-day period. Dosing of modafinil will begin at 200 mg and, depending on the individual, may increase to 400 mg. Citalopram will be given in increasing doses, starting at 20 mg and increasing to 40mg.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals |
Study Start Date : | July 2006 |
Estimated Primary Completion Date : | July 2010 |
Estimated Study Completion Date : | July 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: 1
Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
|
Drug: Modafinil 200mg
10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
|
Experimental: 2
Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
|
Drug: Modafinil 400mg
10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
|
Experimental: 3
Citalopram 20/ Methadone Maintenance 1.2mg/kg
|
Drug: Citalopram 20mg
10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
|
Experimental: 4
Citalopram 40/ Methadone Maintenance 1.2 mg/kg
|
Drug: Citalopram 40mg
10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
|
Placebo Comparator: 5
Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
|
Drug: Placebo
Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
|
- Confirmed abstinence from cocaine [ Time Frame: 12 weeks of treatment ]
- Retention [ Time Frame: 12 weeks of treatment ]
- Medication Compliance [ Time Frame: 12 weeks of treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 22 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Meets cocaine abuse and dependence criteria (as determined by the SCID)
- Meets opiate dependence criteria (as determined by the SCID)
- In good general physical and psychiatric health (except for possible acute drug use related problems)
Exclusion Criteria:
- Meets diagnostic criteria for other psychiatric disorders, including other forms of drug dependence (other than nicotine)
- Current cardiovascular disease (as determined by an electrocardiogram)
- Circumstances will not allow for completion of study (on probation or parole)
- Ethical constraints of supervision do not allow confidentiality (on probation or parole)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00218036
Contact: Laura B Madden-Fuentes, B.A. | 713-500-2563 | Laura.MaddenFuentes@uth.tmc.edu | |
Contact: Ann Garcia, MA | 713-500-2804 | Ann.D.Garcia@uth.tmc.edu |
United States, Texas | |
University of Texas Health Science Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Ann Garcia, MA 713-500-2804 Ann.D.Garcia@uth.tmc.edu | |
Principal Investigator: Richard Meisch, MD, PhD |
Principal Investigator: | Joy M Schmitz, PhD | University of Texas | |
Study Chair: | F. Gerard Moeller, M.D. | University of Texas Medical School at Houston |
Responsible Party: | Joy Schmitz, Ph.D., University of Texas Medical School at Houston |
ClinicalTrials.gov Identifier: | NCT00218036 History of Changes |
Other Study ID Numbers: |
NIDA-09262-8 P50DA009262-08 ( U.S. NIH Grant/Contract ) DPMC ( Other Identifier: NIDA ) |
First Posted: | September 22, 2005 Key Record Dates |
Last Update Posted: | December 15, 2009 |
Last Verified: | December 2009 |
Keywords provided by National Institute on Drug Abuse (NIDA):
Cocaine Abuse Opiate Abuse |
Additional relevant MeSH terms:
Opioid-Related Disorders Cocaine-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Cocaine Methadone Opiate Alkaloids Citalopram Dexetimide Modafinil Armodafinil Anesthetics, Local Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Vasoconstrictor Agents Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Analgesics, Opioid Narcotics Analgesics Antitussive Agents Respiratory System Agents |